|
Mutation Information
|
Mutation Site
|
L180M |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Combined Mutation
|
rt.L180M+rt.M204I;rt.L180M+rt.M204V |
|
Genotype/Subtype
|
B;C |
|
Relevant Drug
|
lamivudine (LAM);entecavir (ETV);adefovir (ADV);telbivudine (LDT) |
|
Country
|
China |
Literature Information
|
PubMed PMID
|
29654894
|
|
Disease
|
HBV infection
|
|
Published Year
|
2018 |
|
Journal
|
International journal of antimicrobial agents |
|
Title
|
Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: A retrospective study. |
|
Author
|
Guo X,Wu J,Wei F,Ouyang Y,Li Q,Liu K,Wang Y,Zhang Y,Chen D |
|
Evidence
|
Despite >50% of M204I/V+/-L180M among all HBV resistance cases annually and extensive exposure of patients to lamivudine (LAM), telbivudine (LdT) and adefovir dipivoxil (ADV), ETV resistance also showed a dramatically increased incidence, which rose to 17.1% in 2016.
|
|
|
HBV Mutation Detail Information